Cargando…

Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719522/ https://www.ncbi.nlm.nih.gov/pubmed/34992369 http://dx.doi.org/10.2147/IJN.S354929

Ejemplares similares

Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin
por: Hu, Xiaolin, et al.
Publicado: (2021)

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
Publicado: (2015)

Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish
por: Chen, Yau-Hung, et al.
Publicado: (2014)

Snake Venom Causes Apoptosis by Increasing the Reactive Oxygen Species in Colorectal and Breast Cancer Cell Lines [Corrigendum]
Publicado: (2022)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients
por: Zheng, Yan-Fu, et al.
Publicado: (2021)

Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin
por: Nara, Katsuhiko, et al.
Publicado: (2023)

Corrigendum to “Hydrogen-Rich Saline Attenuates Cardiac and Hepatic Injury in Doxorubicin Rat Model by Inhibiting Inflammation and Apoptosis”
por: Gao, Yunan, et al.
Publicado: (2017)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study
por: Xiaozhe, Li, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Corrigendum to Quercus pyrenaica Honeydew Honey With High Phenolic Contents Cause DNA Damage, Apoptosis, and Cell Death Through Generation of Reactive Oxygen Species in Gastric Adenocarcinoma Cells
Publicado: (2022)

Corrigendum to “Inhibition of Uncoupling Protein 2 Enhances the Radiosensitivity of Cervical Cancer Cells by Promoting the Production of Reactive Oxygen Species”
por: Liu, Cui Hua, et al.
Publicado: (2021)

High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study
por: Zhao, Yanfang, et al.
Publicado: (2021)

Corrigendum to “Orosomucoid 1 Attenuates Doxorubicin-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Nrf2 Signaling”
por: Cheng, Xiaoli, et al.
Publicado: (2022)

Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters
por: Liang, Guohua, et al.
Publicado: (2021)

Corrigendum to “NCF4 dependent intracellular reactive oxygen species regulate plasma cell formation” [Redox Biol 56 (2022) 102422]
por: He, Chang, et al.
Publicado: (2022)

Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
por: Yokomichi, Noriyuki, et al.
Publicado: (2013)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]
Publicado: (2013)

Tat-Functionalized Liposomes for the Treatment of Meningitis: An in vitro Study [Corrigendum]
Publicado: (2020)

Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide
por: Skubitz, Keith M, et al.
Publicado: (2022)

Corrigendum to “Hydrogen Sulfide Prevents Formation of Reactive Oxygen Species through PI3K/Akt Signaling and Limits Ventilator-Induced Lung Injury”
por: Spassov, Sashko Georgiev, et al.
Publicado: (2017)

Corrigendum to “Anti-Interleukin-16-Neutralizing Antibody Attenuates Cardiac Inflammation and Protects against Cardiac Injury in Doxorubicin-Treated Mice”
por: Zhang, Jianwei, et al.
Publicado: (2022)

CD-340 Functionalized Doxorubicin-Loaded Nanoparticle Induces Apoptosis And Reduces Tumor Volume Along With Drug-Related Cardiotoxicity In Mice [Corrigendum]
Publicado: (2019)

CD-340 Functionalized Doxorubicin-Loaded Nanoparticle Induces Apoptosis and Reduces Tumor Volume Along with Drug-Related Cardiotoxicity in Mice [Corrigendum]
Publicado: (2021)

Corrigendum to “Kinetic Modeling of the Mitochondrial Energy Metabolism of Neuronal Cells: The Impact of Reduced α-Ketoglutarate Dehydrogenase Activities on ATP Production and Generation of Reactive Oxygen Species”
por: Berndt, Nikolaus, et al.
Publicado: (2018)

Corrigendum to “Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo”
por: Marycz, Krzysztof, et al.
Publicado: (2017)

Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
por: Gorini, Stefania, et al.
Publicado: (2019)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
Publicado: (2019)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Corrigendum: Silencing Huwe1 reduces apoptosis of cortical neurons exposed to oxygen-glucose deprivation and reperfusion
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_55cl97q7t4u1tpsv0rkg7rntli